Evotec SE(EVO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 45 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EVO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Evotec SE (EVO), a Healthcare sector company. EVO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 45 institutional filers currently hold this stock. Top institutional holders of EVO by reported 13-F value include Mubadala Investment Co PJSC, DCF Advisers,, WCM INVESTMENT MANAGEMENT,, based on the most recent SEC filings. EVO trades on the Nasdaq exchange and files with the SEC under CIK 1412558. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evotec SE directly from SEC EDGAR.
AI Insight: EVO Ratio Trends
Insufficient data to assess trends — all ratio fields are blank across every reported period.
• No OpMargin, NPM, ROE, ROA, ROIC, or D/E data is available for any period from Q4 2021 through Q4 2024.
⚠ Data unavailability itself warrants caution — inability to assess profitability or leverage trends limits fundamental analysis.
Get alerted when EVO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Evotec SE including:
Top Institutional Holders of EVO
Mubadala Investment Co PJSC
$11.5M4,597,701 shDCF Advisers, LLC
$2.7M1,065,274 shWCM INVESTMENT MANAGEMENT, LLC
$1.5M627,260 shABC ARBITRAGE SA
$1.3M509,050 shOptiver Holding B.V.
$708.9K283,576 shMORGAN STANLEY
$649.4K259,744 shLPL Financial LLC
$305.9K122,346 shENVESTNET ASSET MANAGEMENT INC
$298.5K119,409 shMILLENNIUM MANAGEMENT LLC
$248.9K99,568 shCITADEL ADVISORS LLC
$217.9K87,180 sh
| Fund | Value | Shares |
|---|---|---|
| Mubadala Investment Co PJSC | $11.5M | 4,597,701 |
| DCF Advisers, LLC | $2.7M | 1,065,274 |
| WCM INVESTMENT MANAGEMENT, LLC | $1.5M | 627,260 |
| ABC ARBITRAGE SA | $1.3M | 509,050 |
| Optiver Holding B.V. | $708.9K | 283,576 |
| MORGAN STANLEY | $649.4K | 259,744 |
| LPL Financial LLC | $305.9K | 122,346 |
| ENVESTNET ASSET MANAGEMENT INC | $298.5K | 119,409 |
| MILLENNIUM MANAGEMENT LLC | $248.9K | 99,568 |
| CITADEL ADVISORS LLC | $217.9K | 87,180 |
More Healthcare Companies
View all Healthcare →Put EVO on your watchlist
Track score changes the day Evotec SE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EVO a good stock to buy?
13F Pro's AI-powered analysis of Evotec SE (EVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVO are available on the EVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EVO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evotec SE's investment landscape.